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ABSTRACT: While many point-of-care (POC) diagnostic methods have
been developed for blood-borne analytes, development of saliva-based
POC diagnostics is in its infancy. We have developed a portable microflu-
idic device for detection of potential biomarkers of periodontal disease
in saliva. The device performs rapid microfluidic chip-based immunoas-
says (<3–10 min) with low sample volume requirements (10 L) and
appreciable sensitivity (nM–pM). Our microfluidic method facilitates
hands-free saliva analysis by integrating sample pretreatment (filtering,
enrichment, mixing) with electrophoretic immunoassays to quickly mea-
sure analyte concentrations in minimally pretreated saliva samples. The
microfluidic chip has been integrated with miniaturized electronics, opti-
cal elements, such as diode lasers, fluid-handling components, and data
acquisition software to develop a portable, self-contained device. The
device and methods are being tested by detecting potential biomark-
ers in saliva samples from patients diagnosed with periodontal disease.
Our microchip-based analysis can readily be extended to detection of
biomarkers of other diseases, both oral and systemic, in saliva and other
oral fluids.
KEYWORDS: microfluidics; periodontal disease; diagnostics; point-of-
care; POC; immunoassay; lab-on-a-chip; saliva
Throughout the last decade, research studies using saliva as a diagnostic fluid
have increased exponentially.1 The primary benefits of saliva-based tests, over
more common blood tests, include easier, noninvasive saliva collection, and
the lower costs associated with saliva testing.2–4 The increased interest in
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saliva diagnostics has also been spurred by rapidly accumulating evidence
of correlation between saliva analyte levels and those in serum. Thus, saliva
testing is not only a means to monitor oral health, but is now viewed as a
potential window into the overall systemic health of an individual. Saliva di-
agnosis of autoimmune disorders (i.e., Sjögren’s syndrome), cardiovascular
diseases, abnormal endocrine function, presence of infection (viral, bacte-
rial), renal disease, cancer, and abuse of drugs are all areas that have ben-
efited from using saliva as a diagnostic fluid.1 Saliva testing is also being
explored for directing and monitoring treatment options. For example, drug
doses can be monitored without inconvenient and costly visits to blood-drawing
facilities.
Agencies such as the Office of the Surgeon General5 and the NIDCR6 have
recognized the potential of saliva as a diagnostic fluid and have thus called for
increased research and development of saliva-based testing. While the potential
value of saliva as a diagnostic fluid has become more apparent, the adoption of
saliva as a routine diagnostic fluid has met with three general types of barriers.
As outlined by the 1999 NIDCR workshop for saliva diagnostics development,
barriers to acceptance and use of saliva can be broadly characterized as follows:
need for innovation in accurate analyte measurements in small volumes and
development of standardized saliva collection methods; lack of investment in
product development; and low technology adoption rates by clinicians and
medical insurance companies.
Since 1999, substantial technological barriers to widespread use of saliva
in diagnostics have begun to diminish. Recent development of techniques that
combine the power of miniaturization with cutting-edge discoveries in fields
once as distinct as biology and engineering is leading to rapid, high-throughput,
automated, portable, low-cost, and efficient biochemical analyses with small
sample volumes.
MICROFLUIDIC METHODS CONFER ADVANTAGES TO
DIAGNOSTIC DESIGN AND USAGE PARADIGMS
With recent advances in proteomics and systems biology, it is evident that
multi-parameter diagnostic approaches are needed for clinical use.7 Tradi-
tional single-marker approaches are based on the expectation that a change
in the concentration of a single protein can unambiguously specify disease.
In reality, diseases exhibit great heterogeneity between individuals; the same
disease can be initiated by numerous factors and can cause a range of molecu-
lar changes. Thus, single-marker tests generally suffer from lack of sensitivity
and specificity.8 Diagnostics developed for complex diseases require the anal-
ysis of multiple components to effectively (1) predict the onset of disease,
(2) stratify disease (e.g., prostate cancer could be subcategorized as three or
four distinct diseases), (3) indicate the progression of the disease, (4) direct
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treatment (identify resistance to drugs or potential adverse reactions, etc.), and
(5) monitor treatment. For each type of disease, the informative set of markers
will be different. To accomplish this goal, low-cost high-throughput methods
that safely make use of small sample volumes are necessary.
Researchers have envisioned miniaturized diagnostic technologies that could
accurately ascertain disease states using droplets (tens of microliters) of hu-
man body fluid. Recent reports describe lab-on-a-chip instruments that per-
form multiple operations in parallel in extralaboratory settings (i.e., field de-
ployment, near-patient environments, and resource-poor settings).9–11 Cur-
rent technologies not only provide paths toward such implementation, but
are also presently being exploited and demonstrated. While recent reports
show promise for microfluidic detection of analytes in various body flu-
ids,11–14 few, if any, reports on detection of endogenous biomarkers in saliva
using a semiportable instrument have been made. We believe that operating
specifications for such instrumentation can be described by the following
characteristics:
(1) Saliva-based: Ready collection of samples by trained or untrained per-
sonnel.
(2) Microfluidic: Requires small volumes of saliva.
(3) Multiplexed detection: Simultaneous analysis of multiple analytes for
accurate assessment of complex diseases.
(4) Portable and easy to use: Point-of-care (POC) testing with simple user
interface.
(5) Rapid: Simultaneous protein measurements within a routine clinical visit.
(6) Low cost: Feasible widespread screening, diagnosis, and monitoring.
Key advances in bioanalytical instrument design, both at Sandia and else-
where, have relied upon microfluidic technologies to enable sensitive and
fast analyses, especially for manipulation of sub-microliter fluid volumes.
Such significant technological advances in miniaturization (at the micro- and
nanoscales) have led to the advent of valuable new diagnostic formats, known
as “lab-on-a-chip” devices.
Realizing the potential miniaturization and automation made possible
through the lab-on-a-chip paradigm requires integration of various function-
alities. Incorporation of unit functionalities (fluid containment and fluid han-
dling in channels similar in dimensions to a human hair; hands-free operation
of sample preparation steps; automated bioanalytical assays; integrated optical
systems for fluorescence-based detection; and subsequent reporting of assay
results) is essential to conduct sophisticated analyses. Sandia has recently re-
ported one of the first lab-on-a-chip systems to demonstrate full integration
and hand-portable operation.9 Innovation regarding portable, rapid, specific
bioanalytical methods and associated hardware has been undertaken at Sandia
for applications ranging from biotoxin detection9,15,16 to proteomics17–19 to
cell sorting20,21 and clinical diagnostics.22
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Building on technologies introduced above, our group is actively developing
an integrated microfluidic platform for oral diagnostics (IMPOD). An image of
an early hardware version of the portable diagnostic is based on that developed
at Sandia previously9 and is shown in FIGURE 1. A descriptive summary of
the technology is given in TABLE 1. IMPOD, as well as quantitative, portable
instrumentation like it, has the potential to be translated to clinical settings for
use in rapid, near-patient analysis of human saliva and oral fluids. The methods
and technologies presented here also have applicability to nonoral diagnostic
fluids, as well as other local and systemic diseases.
MICROFLUIDIC ELECTROPHORETIC IMMUNOASSAYS AS
CORE ANALYTICAL METHOD
Use of microfluidic technologies naturally confers assay speed, low-reagent
volume consumption, and streamlined sample preparation and assay inte-
gration to the IMPOD diagnostic platform. By incorporating photopolymer-
ized cross-linked polyacrylamide gels within a microfluidic device and using
immunoassays, we have further conferred high-resolution sieving-based per-
formance and fine specificity to the microanalytical platform.
Combining the specificity and selectivity typical of conventional immunoas-
says with high-efficiency separations achieved by microfluidic methods, our
demonstrated technology efficiently separates receptor-bound and unbound
species, resulting in quantitation of only those analytes of interest. A schematic
description of the assay protocol is in FIGURE 2. Such an approach avoids
FIGURE 1. Image of early generation IMPOD with hardware components labeled.
Inset shows glass microdevice used in performing immunoassays.
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TABLE 1. Summary of IMPOD characteristics
Automated operation
Manual volume-independent sample introduction via syringe
or pipette (no volume dependence, if > 50 L)
Automated sample preparation and associated timing
Integrated high-voltage power supply (drives mixing,
preconcentration, and electrophoresis)
Automated assay and replicate runs (timing)
Electronic data collection via software interface
Sample introduction and pre-processing
Off-chip: centrifugation and dilution
On-chip: debris removal (filtering); sample preconcentration; rapid mixing
Microfluidic immunoassay specificity and selectivity
Multiplexing: serial format demonstrated; parallel format in testing stage
“Capture chemistry”: high-affinity, fluorescent receptors provide specificity
Tunable sieving matrix provides assay selectivity and resolution
Analysis of saliva from subjects in both healthy
and periodontal-diseased categories
Gold-standard results comparison via validation assays (ELISA, protein microarray)
Miniaturized detection system
Fluorescent receptor molecules provide specific detection signal
Diode laser induced fluorescence excitation
Photomultiplier tube (PMT) fluorescence detection
Data analysis
Software-based data analysis (research stage)
problems associated with open-channel protein electrophoresis. Polyacry-
lamide gel electrophoresis (PAGE) has been used for decades for protein anal-
ysis and does not exhibit nonspecific adsorption of proteins. Channel surfaces
are coated with linear polyacrylamide23,24 using photoinitiated polymerization.
Cross-linked polyacrylamide gels are made in situ by photopolymerization us-
ing methods reported by our group.25,26
Electrophoretic immunoassays offer a number of advantages over con-
ventional radioimmunoassays or enzyme-linked immunosorbent assays
(ELISA).27 Capillary electrophoresis is a highly effective separation method
allowing separation of bound from unbound species in a single step, thus
eliminating the multiple wash steps required in conventional immunoassays.
Immobilization of reporter molecules (antibodies) on sensor surfaces is unnec-
essary. Electrophoretic immunoassays are typically performed in an open or
surface-modified microfluidic channel.28–31 In contrast to conventional capil-
lary zone electrophoresis approaches, we have relied upon sieving–gel-based
electrophoretic immunoassays, as open channel (or free solution) immunoas-
says suffer from a number of disadvantages:
(1) Difficulty in attaining adequate species discrimination with electrophore-
sis-based immunoassays on account of the small differences in charge-
to-mass characteristics between large antibodies and immune complexes.
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FIGURE 2. Microchip-based electrophoretic immunoassays. (left) Protocol schematic:
Binding/Preconcentration: The sample is mixed with a known amount of fluorescently la-
beled antibody. The mixing is done off-chip or on-chip. During initial methods development,
we carry out the mixing outside the chip (requires ∼15 min). Upon optimization of im-
munoassay conditions, the sample and the labeled antibody are added to different reservoirs
in the sample manifold and are mixed (in <3 min) electrokinetically on-chip. Separation:
Mixed sample is electrophoretically injected into a separation channel. The antibody-bound
antigen and unbound antibody are separated based on size and charge by native polyacry-
lamide gel electrophoresis. Detection & Analysis: A laser-induced fluorescence detector
detects the unbound antibody and bound antibody (i.e., immune complex) peaks. Migration
times are recorded and peak areas are calculated. The immunoassay is repeated with sam-
ples containing known amounts of analyte to generate a multi-point calibration curve. The
calibration curve is used to estimate the concentration of analyte in the unknown sample.
(right) Image of glass microdevice.
(2) Vulnerability to analyte dispersion arising from difficult-to-control hy-
drodynamic flow.
(3) Difficulty associated with integration of open channel components with
complex chip-based systems (e.g., sample preprocessing functionalities).
The microfluidic components that form the core of IMPOD integrate multiple
functions (e.g., sample injection, mixing and incubation with antibodies, sam-
ple enrichment, and separation of bound and unbound immune complexes).
The immunoassays themselves take minutes to complete (compared to hours
for conventional quantitative ELISA) and are capable of analyzing sample
volumes of less than 10 L. Integration of parallel analyses using multichan-
nel chips and spectral multiplexing for simultaneous multi-analyte analysis
is currently under way. Integrated sample enrichment improves the detection
limit to the low picomolar range.32
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PROTEIN BIOMARKERS FOR CLINICAL DIAGNOSIS
OF PERIODONTAL DISEASE
Saliva is a fluid that can be easily collected, contains locally derived and
systemically derived biomarkers of periodontal disease, and hence may offer
the basis for a patient-specific biomarker assessment for periodontitis and
other systemic diseases. Periodontitis is a group of inflammatory diseases
affecting the connective tissue attachment and supporting bone around the
teeth. Once initiated, the disease progresses with the loss of tooth-supporting
collagen fibers and attachment to the cemental surface, apical migration of
the junctional epithelium, formation of deepened periodontal pockets, and re-
sorption of alveolar bone. If left untreated, the disease continues with pro-
gressive bone destruction, leading to tooth mobility and subsequent tooth
loss. Periodontal disease afflicts over 50% of the adult population in the
United States, with approximately 10% displaying severe disease concomitant
with early tooth loss. Recent evidence suggests a strong association among
periodontal disease, cardiovascular disease, and pulmonary and other serious
systemic diseases.
Because of the noninvasive and undemanding nature of saliva collection,
analysis of saliva may be especially beneficial in the determination of cur-
rent periodontal status and a means of monitoring the response to treatment.
Studies report that the determination of inflammatory mediator levels in bi-
ological fluids is a good indicator of inflammatory activity.33 Accordingly,
studies related to the pathogenesis of periodontal disease examine the link
between biochemical and immunological markers in saliva and the extent of
periodontal destruction-–with potential for predicting future disease progres-
sion. Oral fluid biomarkers studied for periodontal diagnosis include proteins
of host origin (i.e., enzymes and immunoglobulins), phenotypic markers, host
cells, hormones, bacteria and bacterial products, ions and volatile compounds.
There are a variety of other biomarkers of skeletal homeostasis. These biomark-
ers may have significant potential in other bone metabolic diseases, such as
osteoporosis, rheumatoid arthritis, and osteolytic bone metastases.
Risk factors are considered to be modifiers of the nature of disease. Asso-
ciated with host susceptibility and a variety of local and systemic conditions,
risk factors influence the initiation and progression of periodontitis and alter
biomarker levels. Longitudinal studies of biomarkers play an important role
in life sciences and have begun to assume a greater role in diagnosis, moni-
toring of therapy outcomes, and drug discovery. The challenge for biomarkers
is to allow earlier detection of the disease evolution and more robust assess-
ment of therapeutic efficacy. For biomarkers to assume their rightful role, a
greater understanding of the mechanism of disease progression and therapeu-
tic intervention is essential. Consequently, there is a need for the development
of new diagnostic tests that can detect the presence of active disease, fore-
cast future disease progression, and evaluate the response to periodontal ther-
HERR et al. 369
apy, thereby improving the clinical management of periodontal patients. The
diagnosis of active phases of periodontal disease and the identification of
patients at risk for active disease represent challenges for both clinical inves-
tigators and practitioners.
ONGOING CLINICAL MEASUREMENTS USE IMPOD
Our group has recently demonstrated the ability to measure putative protein
biomarkers in whole saliva, gingival crevicular fluid (GCF), and other oral flu-
ids. We have completed a pilot analysis in a recent cross-sectional investigation
of periodontal disease and health, as well as recently published evaluation of
protein biomarkers in oral fluids during periodontal reconstructive therapy us-
ing local34,35 or systemic drug delivery.36 Our studies employing the IMPOD
diagnostic have shown the reproducible assessment of putative periodontal
disease biomarkers.37 FIGURE 3 shows IMPOD analysis of saliva for two cy-
tokines, tumor necrosis factor- (TNF-) and interleukin-6 (IL-6). While these
results demonstrate IMPOD-based measurement of spiked cytokines in whole
saliva, the data show how rapid the analyses are (completed in less than 250
sec) and that the assays are quantitative—allowing generation of calibration
curves for measurement of endogenous saliva in pilot samples.
Low nanomolar detection limits are not always adequate for screening of
low-abundance disease markers.38 Our group has demonstrated experience
with development of on-chip functional components (e.g., dialysis mem-
branes,39 buffer exchange membranes,40 and pressure-actuated valving18,41)
using photolithographically controlled polymerization. We employ these fab-
rication methods to create size-exclusion membranes within microfluidic chan-
nels for sample concentration or enrichment. The pore size of the miniaturized
size-exclusion membrane is controlled via the formulation of the precursor
solution (monomer and cross-linker).
Our group has shown that the incorporation of photolithographically fabri-
cated size-exclusion membranes has extended the sensitivity of protein-sizing
assays to the femtomolar level.32 When implemented with our electrokinetic
immunoassays, online sample enrichment allows rapid identification (<10
min) of protein markers in human saliva at clinically relevant concentrations
(10−12 M) without the need for additional off-chip sample preparation. Trap-
ping of analytes in the volume near the membrane obviates the need for off-chip
sample incubation and reporter-binding steps. FIGURE 4 shows results from the
high-sensitivity IMPOD immunoassay technique, compared to immunoassays
not incorporating sample enrichment, for analysis of C-reactive protein (CRP).
An appreciable increase in assay sensitivity is observed when IMPOD operates
using sample enrichment. Further, the duration of sample (as well as antibody)
enrichment can be used to “tune” the assay sensitivity and dynamic range in
real time, thus making a single assay applicable to measurement of both high-
and low-abundance protein species in a given diagnostic sample.
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A key, defining feature of our microfluidic approach is development of an
instrument that readily measures multiple analytes simultaneously. Such an ap-
proach is essential for early and accurate diagnosis of a chronic inflammatory
disease, such as periodontitis, where measuring overall “composite profile”
or “signature” of a set of biomarkers may have significantly higher diagnos-
tic value than measurement of individual analytes. In addition to measuring
endogenous protein content in saliva using the IMPOD approach, our group
is assessing a large panel of putative biomarkers for relevance to periodontal
disease. Data currently being generated from these proteomic measurements
FIGURE 3. IMPOD analysis is quantitative and completes in less than four minutes.
(Top) Electropherograms for exogenous TNF- analysis in whole saliva. Companion dose-
response curve acquired in model buffer system. (Bottom) IL-6 measurements from IMPOD
analysis of spiked whole saliva. Companion dose-response curve from spiked saliva.
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FIGURE 4. On-chip sample enrichment extends the C-reactive protein dynamic range
and increases the sensitivity of IMPOD. Buffer samples spiked with known concentrations
of C-RP were analyzed with (solid squares) and without (hollow circles) on-chip sample
enrichment. Measurement of C-RP in spiked whole saliva, without enrichment, is shown
for comparison (solid circles).
allow us to gauge the predictive ability of putative disease biomarkers (cy-
tokines, enzymes, and bone collagen fragments). Currently, the use of digi-
tal subtraction radiography and longitudinal clinical parameter assessment is
being compared to oral fluid samples (saliva, GCF) to develop the appropriate
metrics in evaluating the interrelationship of disease biomarkers to various
fluid components.
Analyte classes, shown here in order of progression of periodontal disease,
are currently being evaluated for their predictive value in diagnosis of pe-
riodontal disease by our group and others: (1) inflammatory mediators and
host-response modifiers (Th1/Th2 cytokines and CRP), (2) host-derived en-
zymes (collagenases, gelatinases), (3) connective and bone breakdown pro-
teins (osteocalcin, osteonectin, laminin, C-telopeptide pyridinoline cross-links
[ICTP]). Our preliminary proteomic studies suggest that at least three analytes
(IL-1B, MMP-8, and ICTP) have significant correlation with the progression
of periodontal disease. Each of these three analytes is implicated in a different
stage of periodontal disease progression. Further work regarding identification
and validation of these protein biomarkers is currently under way by our group.
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CONCLUSIONS
Over the past 3 years, our collaborative project has focused on the devel-
opment of a novel diagnostic strategy for the evaluation of human periodontal
disease. A goal of periodontal diagnostic procedures is to provide the clinician
with useful information regarding the present periodontal disease type, loca-
tion, and severity. These findings serve as a basis upon which treatment plan-
ning is formulated and provide useful information during periodontal main-
tenance and disease monitoring phases of treatment. Traditional periodontal
diagnostic parameters used by clinicians include several semisubjective assess-
ment parameters, many of which develop during advanced disease. Advances
in oral and diagnostic research are moving toward methods by which peri-
odontal risk can be identified and quantified by objective measures, such as
biomarkers that can be determined in a rapid fashion, such as is the case with
our IMPOD instrument.
Ongoing work centers on identification and validation of panels of protein
biomarkers, with particular emphasis on identifying groups of proteins that
have relevance to all stages of periodontal disease progression—both as a
means to enable early diagnosis of periodontal disease and as a means to assess
the activity of disease in a particular patient or site. Our group is working to
incorporate the capability for multiplex analyses (i.e., assaying a single sample
for multiple biomarkers in parallel). Lastly, the research reported here lays the
groundwork for extension of these methods to other diagnostic fluids and
illnesses. Clinical and engineering approaches, such as those described in this
work, present compelling advantages for furthering personalized medicine in
the 21st century.
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